Textron Inc. (FRA:TXT)
Germany · Delayed Price · Currency is EUR 66.68
-1.50 (-2.20%)
At close: Aug 1, 2025, 10:00 PM CET
Inozyme Pharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 28, 2025 | Dec '24 Dec 28, 2024 | Dec '23 Dec 30, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Jan '21 Jan 2, 2021 | 2016 - 2020 |
Net Income | 816 | 824 | 921 | 861 | 746 | 309 | Upgrade |
Depreciation & Amortization | 396 | 382 | 395 | 397 | 390 | 391 | Upgrade |
Loss (Gain) From Sale of Assets | -4 | - | - | - | -17 | - | Upgrade |
Asset Writedown & Restructuring Costs | 41 | 41 | 88 | 2 | 13 | 116 | Upgrade |
Other Operating Activities | 90 | 79 | -99 | -117 | 114 | 88 | Upgrade |
Change in Accounts Receivable | -52 | -96 | -9 | -26 | -58 | 149 | Upgrade |
Change in Inventory | -11 | -194 | -359 | -55 | 45 | 434 | Upgrade |
Change in Accounts Payable | -13 | -69 | 2 | 235 | 13 | -613 | Upgrade |
Change in Income Taxes | 10 | -26 | 4 | 18 | 11 | -62 | Upgrade |
Change in Other Net Operating Assets | -355 | 74 | 324 | 175 | 342 | -43 | Upgrade |
Operating Cash Flow | 917 | 1,014 | 1,266 | 1,488 | 1,598 | 768 | Upgrade |
Operating Cash Flow Growth | -21.42% | -19.91% | -14.92% | -6.88% | 108.07% | -24.26% | Upgrade |
Capital Expenditures | -358 | -364 | -402 | -354 | -375 | -317 | Upgrade |
Sale of Property, Plant & Equipment | 10 | 4 | 18 | 22 | 3 | 33 | Upgrade |
Cash Acquisitions | -1 | -13 | -1 | -202 | - | -15 | Upgrade |
Divestitures | 16 | - | - | - | 38 | - | Upgrade |
Other Investing Activities | 190 | 85 | 42 | 67 | 34 | 29 | Upgrade |
Investing Cash Flow | -156 | -284 | -317 | -447 | -281 | -248 | Upgrade |
Short-Term Debt Issued | - | - | - | - | - | 377 | Upgrade |
Long-Term Debt Issued | - | - | 348 | - | - | 1,137 | Upgrade |
Total Debt Issued | 495 | - | 348 | - | - | 1,514 | Upgrade |
Short-Term Debt Repaid | - | -1 | - | -14 | -1 | -377 | Upgrade |
Long-Term Debt Repaid | - | -377 | -44 | -234 | -621 | -593 | Upgrade |
Total Debt Repaid | -368 | -378 | -44 | -248 | -622 | -970 | Upgrade |
Net Debt Issued (Repaid) | 127 | -378 | 304 | -248 | -622 | 544 | Upgrade |
Issuance of Common Stock | 25 | 88 | 73 | 44 | 116 | 22 | Upgrade |
Repurchase of Common Stock | -876 | -1,122 | -1,168 | -867 | -921 | -183 | Upgrade |
Common Dividends Paid | -11 | -12 | -16 | -17 | -18 | -18 | Upgrade |
Other Financing Activities | -20 | -30 | -6 | -3 | -1 | -5 | Upgrade |
Financing Cash Flow | -755 | -1,454 | -813 | -1,091 | -1,446 | 360 | Upgrade |
Foreign Exchange Rate Adjustments | 17 | -16 | 10 | -32 | -8 | 17 | Upgrade |
Net Cash Flow | 23 | -740 | 146 | -82 | -137 | 897 | Upgrade |
Free Cash Flow | 559 | 650 | 864 | 1,134 | 1,223 | 451 | Upgrade |
Free Cash Flow Growth | -27.40% | -24.77% | -23.81% | -7.28% | 171.18% | -33.18% | Upgrade |
Free Cash Flow Margin | 3.98% | 4.74% | 6.31% | 8.81% | 9.88% | 3.87% | Upgrade |
Free Cash Flow Per Share | 3.02 | 3.42 | 4.28 | 5.28 | 5.40 | 1.97 | Upgrade |
Cash Interest Paid | 142 | 142 | 122 | 123 | 145 | 159 | Upgrade |
Cash Income Tax Paid | 191 | 191 | 352 | 356 | 93 | 42 | Upgrade |
Levered Free Cash Flow | 617.25 | 706.88 | 991.75 | 1,331 | 1,042 | 550.5 | Upgrade |
Unlevered Free Cash Flow | 676 | 755.63 | 1,031 | 1,390 | 1,119 | 641.13 | Upgrade |
Change in Net Working Capital | 123 | 39 | -146 | -586 | -338 | -117 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.